We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.75 | 0.99% | 76.55 | 55.00 | 77.24 | 76.49 | 75.43 | 76.47 | 9,026,349 | 05:00:07 |
From May 2022 to May 2024
By Joe Hoppe
C4X Discovery Holdings PLC said Monday that it has signed a worldwide licensing deal with AstraZeneca PLC worth up to $402 million for the development and commercialization of its NRF2 Activator program.
The drug discovery company said it was eligible to receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. The deal also includes payments for development and commercial milestones, and tiered mid-single digit royalties.
The company said AstraZeneca will develop and commercialize an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic obstructive pulmonary disease.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
November 28, 2022 02:49 ET (07:49 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
